scholarly journals Synthesis and preliminary biological evaluation of O-2((2-[18F]fluoroethyl)methylamino)ethyltyrosine ([18F]FEMAET) as a potential cationic amino acid PET tracer for tumor imaging

Amino Acids ◽  
2014 ◽  
Vol 46 (8) ◽  
pp. 1947-1959 ◽  
Author(s):  
Aristeidis Chiotellis ◽  
Adrienne Müller ◽  
Karin Weyermann ◽  
Dominique S. Leutwiler ◽  
Roger Schibli ◽  
...  
Keyword(s):  
Amino Acid ◽  
Tumor Imaging ◽  
Biological Evaluation ◽  
Cationic Amino Acid ◽  
Pet Tracer ◽  
Amino Acid Pet

Synthesis and preliminary biological evaluation of S-11C-methyl-d-cysteine as a new amino acid PET tracer for cancer imaging

Amino Acids ◽  
2014 ◽  
Vol 47 (4) ◽  
pp. 719-727 ◽  
Author(s):  
Tingting Huang ◽  
Ganghua Tang ◽  
Hongliang Wang ◽  
Dahong Nie ◽  
Xiaolan Tang ◽  
...  
Keyword(s):  
Amino Acid ◽  
Cancer Imaging ◽  
Biological Evaluation ◽  
Pet Tracer ◽  
Amino Acid Pet

scholarly journals Comparison of Amino Acid PET to Advanced and Emerging MRI Techniques for Neurooncology Imaging: A Systematic Review of the Recent Studies

2021 ◽  
Vol 2021 ◽  
pp. 1-19
Author(s):  
Brittany M. Stopa ◽  
Csaba Juhász ◽  
Sandeep Mittal
Keyword(s):  
Systematic Review ◽  
Amino Acid ◽  
Brain Tumors ◽  
Tumor Imaging ◽  
Imaging Techniques ◽  
Diagnostic Potential ◽  
Cest Imaging ◽  
Pubmed Search ◽  
Amino Acid Pet ◽  
Improved Performance

Introduction. Standard neuroimaging protocols for brain tumors have well-known limitations. The clinical use of additional modalities including amino acid PET (aaPET) and advanced MRI (aMRI) techniques (including DWI, PWI, and MRS) is emerging in response to the need for more accurate detection of brain tumors. In this systematic review of the past 2 years of the literature, we discuss the most recent studies that directly compare or combine aaPET and aMRI for brain tumor imaging. Methods. A PubMed search was conducted for human studies incorporating both aaPET and aMRI and published between July 2018 and August 2020. Results. A total of 22 studies were found in the study period. Recent studies of aaPET with DWI showed a superiority of MET, FET, FDOPA, and AMT PET for detecting tumor, predicting recurrence, diagnosing progression, and predicting survival. Combining modalities further improved performance. Comparisons of aaPET with PWI showed mixed results about spatial correlation. However, both modalities were able to detect high-grade tumors, identify tumor recurrence, differentiate recurrence from treatment effects, and predict survival. aaPET performed better on these measures than PWI, but when combined, they had the strongest results. Studies of aaPET with MRS demonstrated that both modalities have diagnostic potential but MET PET and FDOPA PET performed better than MRS. MRS suffered from some data quality issues that limited analysis in two studies, and, in one study that combined modalities, overall performance actually decreased. Four recent studies compared aaPET with emerging MRI approaches (such as CEST imaging, MR fingerprinting, and SISTINA), but the initial results remain inconclusive. Conclusions. aaPET outperformed the aMRI imaging techniques in most recent studies. DWI and PWI added meaningful complementary data, and the combination of aaPET with aMRI yielded the best results in most studies.

Radiosynthesis of 1-[18F]fluoroethyl-L-tryptophan as a novel potential amino acid PET tracer

2012 ◽  
Vol 70 (4) ◽  
pp. 676-680 ◽  
Author(s):  
Ting Sun ◽  
Ganghua Tang ◽  
Hua Tian ◽  
Xiaoyan Wang ◽  
Xianghua Chen ◽  
...  
Keyword(s):  
Amino Acid ◽  
Pet Tracer ◽  
Amino Acid Pet

scholarly journals 18F-FACBC PET/MRI in the evaluation of human brain metastases: a case report

2021 ◽  
Vol 5 (1) ◽  
Author(s):  
Knut Johannessen ◽  
Erik Magnus Berntsen ◽  
Håkon Johansen ◽  
Tora S. Solheim ◽  
Anna Karlberg ◽  
...  
Keyword(s):  
Case Report ◽  
Clinical Practice ◽  
Amino Acid ◽  
Brain Metastases ◽  
Metastatic Cancer ◽  
Low Grade ◽  
Pet Tracer ◽  
Before And After ◽  
Amino Acid Pet ◽  
And Function

Abstract Background Patients with metastatic cancer to the brain have a poor prognosis. In clinical practice, MRI is used to delineate, diagnose and plan treatment of brain metastases. However, MRI alone is limited in detecting micro-metastases, delineating lesions and discriminating progression from pseudo-progression. Combined PET/MRI utilises superior soft tissue images from MRI and metabolic data from PET to evaluate tumour structure and function. The amino acid PET tracer 18F-FACBC has shown promising results in discriminating high- and low-grade gliomas, but there are currently no reports on its use on brain metastases. This is the first study to evaluate the use of 18F-FACBC on brain metastases. Case presentation A middle-aged female patient with brain metastases was evaluated using hybrid PET/MRI with 18F-FACBC before and after stereotactic radiotherapy, and at suspicion of recurrence. Static/dynamic PET and contrast-enhanced T1 MRI data were acquired and analysed. This case report includes the analysis of four 18F-FACBC PET/MRI examinations, investigating their utility in evaluating functional and structural metastasis properties. Conclusion Analysis showed high tumour-to-background ratios in brain metastases compared to other amino acid PET tracers, including high uptake in a very small cerebellar metastasis, suggesting that 18F-FACBC PET can provide early detection of otherwise overlooked metastases. Further studies to determine a threshold for 18F-FACBC brain tumour boundaries and explore its utility in clinical practice should be performed.

scholarly journals Maximizing the use of batch production of 18F-FDOPA for imaging of brain tumors to increase availability of hybrid PET/MR imaging in clinical setting

2020 ◽  
Author(s):  
M S Aboian ◽  
R Barajas ◽  
J Shatalov ◽  
V Ravanfar ◽  
E Bahroos ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Amino Acid ◽  
Brain Tumors ◽  
Pet Imaging ◽  
Critical Role ◽  
Normal Brain ◽  
Mri Imaging ◽  
Pet Tracer ◽  
Amino Acid Pet ◽  
The Cost

Abstract Background Amino acid PET imaging of brain tumors has been shown to play an important role in predicting tumor grade, delineation of tumor margins, and differentiating tumor recurrence from the background of post-radiation changes, but is not commonly used in clinical practice due to high cost. We propose that PET/MRI imaging of patients grouped to the day of tracer radiosynthesis will significantly decrease the cost of PET imaging, which will improve patient access to PET. Methods Seventeen patients with either primary brain tumors or metastatic brain tumors were recruited for imaging on 3T PET/MRI and were scanned on 4 separate days in groups of 3-5 patients. The first group of consecutively imaged patients contained three patients, followed by two groups of 5 patients, and last group of 4 patients. Results For each of the patients, standard of care gadolinium enhanced MRI and dynamic PET imaging with 18F-FDOPA amino acid tracer was obtained. The total cost savings of scanning 17 patients in batches of 4 as opposed to individual radiosynthesis was 48.5% ($28,321). Semiquantitative analysis of tracer uptake in normal brain were performed with appropriate accumulation and expected subsequent washout. Conclusion Amino acid PET tracers have been shown to play a critical role in characterization of brain tumors but their adaptation to clinical practice has been limited due to high cost of PET. Scheduling patient imaging to maximally utilize the radiosynthesis of imaging tracer significantly reduces the cost of PET and results in increased availability of PET tracer use in neuro-oncology.

Amino Acid PET Tracer Accumulation in Cortical Ischemia

2010 ◽  
Vol 35 (11) ◽  
pp. 907-908 ◽  
Author(s):  
Christof Rottenburger ◽  
Soroush Doostkam ◽  
Marco Prinz ◽  
Stephan Meckel ◽  
Guido Nikkhah ◽  
...  
Keyword(s):  
Amino Acid ◽  
Pet Tracer ◽  
Amino Acid Pet ◽  
Cortical Ischemia ◽  
Tracer Accumulation

scholarly journals Radiosynthesis and preliminary biological evaluation of N-(2-[18F]fluoropropionyl)-L-glutamine as a PET tracer for tumor imaging

Oncotarget ◽  
2016 ◽  
Vol 7 (23) ◽  
pp. 34100-34111 ◽  
Author(s):  
Caihua Tang ◽  
Ganghua Tang ◽  
Siyuan Gao ◽  
Shaoyu Liu ◽  
Fuhua Wen ◽  
...  
Keyword(s):  
Tumor Imaging ◽  
Biological Evaluation ◽  
Pet Tracer

scholarly journals S-11C-Methyl-L-Cysteine: A New Amino Acid PET Tracer for Cancer Imaging

2011 ◽  
Vol 52 (2) ◽  
pp. 287-293 ◽  
Author(s):  
H. Deng ◽  
X. Tang ◽  
H. Wang ◽  
G. Tang ◽  
F. Wen ◽  
...  
Keyword(s):  
Amino Acid ◽  
Cancer Imaging ◽  
Pet Tracer ◽  
Amino Acid Pet

scholarly journals Amino Acid Transporters on the Guard of Cell Genome and Epigenome

Cancers ◽  
2021 ◽  
Vol 13 (1) ◽  
pp. 125
Author(s):  
Uğur Kahya ◽  
Ayşe Sedef Köseer ◽  
Anna Dubrovska
Keyword(s):  
Amino Acid ◽  
Cancer Metabolism ◽  
Tumor Imaging ◽  
Redox Homeostasis ◽  
Amino Acid Uptake ◽  
Metabolic Reprogramming ◽  
Tumor Evolution ◽  
Amino Acid Transporters ◽  
Acid Uptake ◽  
Growth And Survival

Tumorigenesis is driven by metabolic reprogramming. Oncogenic mutations and epigenetic alterations that cause metabolic rewiring may also upregulate the reactive oxygen species (ROS). Precise regulation of the intracellular ROS levels is critical for tumor cell growth and survival. High ROS production leads to the damage of vital macromolecules, such as DNA, proteins, and lipids, causing genomic instability and further tumor evolution. One of the hallmarks of cancer metabolism is deregulated amino acid uptake. In fast-growing tumors, amino acids are not only the source of energy and building intermediates but also critical regulators of redox homeostasis. Amino acid uptake regulates the intracellular glutathione (GSH) levels, endoplasmic reticulum stress, unfolded protein response signaling, mTOR-mediated antioxidant defense, and epigenetic adaptations of tumor cells to oxidative stress. This review summarizes the role of amino acid transporters as the defender of tumor antioxidant system and genome integrity and discusses them as promising therapeutic targets and tumor imaging tools.

Sign in / Sign up

Export Citation Format

Share Document